TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference

Rhea-AI Summary

TYME Technologies, an emerging biotechnology company focused on cancer metabolism-based therapies (CMBTs™), announced that CEO Richie Cunningham and CBO Jonathan Eckard will present at the H.C. Wainwright Bioconnect Virtual Conference on January 10, 2022, at 7:00 AM ET. The presentation will be available on demand on the TYME website and archived for 90 days. TYME is developing compounds like SM-88 for various advanced cancers, emphasizing low toxicity and patient quality of life.

BEDMINSTER, N.J.--(BUSINESS WIRE)--

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference as follows:

Date:		Monday, January 10, 2022
On Demand:		7:00AM ET
Webcast:		https://journey.ct.events/view/8689e139-56fc-489f-a7ff-f600798ac5b3

The presentation will be available on demand beginning on January 10, 2022, at 7:00 a.m. ET and will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.

The Company is currently developing its lead novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.

For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005237/en/

INVESTOR AND MEDIA CONTACT:

In-Site Communications

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

Source: TYME Technologies, Inc.

FAQ

What is the date of the TYME presentation at the H.C. Wainwright Conference?

The TYME presentation will take place on January 10, 2022.

What time will the TYME presentation be available on demand?

The presentation will be available on demand starting at 7:00 AM ET.

Where can I find the TYME presentation after the event?

The presentation can be accessed on the Events & Presentations page of the TYME website.

What is SM-88 related to TYME Technologies?

SM-88 is a lead compound being developed by TYME for various advanced cancers.

What types of cancers does TYME's lead compound target?

TYME's lead compound, SM-88, targets multiple advanced cancers, including pancreatic, prostate, sarcomas, and breast cancers.